All News
ACR20 - Day 2 Report
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Read Article
Nurses Health Study results - live healthy & 40% less chance of Getting #SLE #lupus. Not an easy recipe - diet in top 40%, never smoking, regular exercise, modest ETOH, normal BMI. Abstr#1473 Maybe that is why SLE is in the rise Abstr#0274 @RheumNow @CRASCRRheum https://t.co/qYCkYC6Mqq
Janet Pope Janetbirdope ( View Tweet)
#ACR20 Dr. M. Crow on Lupus #StateofArtLecture reviews treatment of SLE:
1. HCQ is the foundation of Rx
2. keep pred <7.5mg/day
3. belimumab works better when given early in disease (<2 yrs)
4. combination Rx may be needed
@rheumnow https://t.co/6zh1xkLXgN
k dao KDAO2011 ( View Tweet)
So much more work to be done- the traditional tools for estimating CVD in rheumatic patients are likely not accurate especially patients with SLE- abstract 1286 @RheumNow #acr20 https://t.co/L6Z1fsO2he
alexa meara lexmeara ( View Tweet)
Dr @AliDuarteMD presents on incidence of SLE over last 40 years, 29% increase overall, and doubled in males. Overall cyclical pattern. Abstr#1024 #ACR20 @rheumnow https://t.co/SSVY0U0SIg
Richard Conway RichardPAConway ( View Tweet)
Another addition to "Where you live matters!" NYC principal component analysis of 140 neighborhood characteristics show - location and SES influence incidence and severity of #COVID19 in #SLE @rheumnow #ACR20 ABS#0984
Bella Mehta bella_mehta ( View Tweet)
Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pathologic Manifestations of Systemic Lupus Erythematosus https://t.co/hAqngljp2b #sle #tollreceptorinhib TLR inhib in mice for SLE
Peter Nash drpnash ( View Tweet)
TMA and SLE by Dr Levy @SickKidsNews
👉TMA triad - microangiopathic hemolytic anemia, thrombocytopenia, impaired renal function
👉TTP pentad - fever, thrombocytopenia, hemolytic anemia, renal impairment, neurologic involvement
#ACR20 #ACRambassador https://t.co/xnO1JkhSFT
Herman Tam DrPedsRheum ( View Tweet)
Neighbourhood characteristics & socioeconomic factors important not only for contracting #COVID19 but also severe infection in #SLE. Results useful for developing strategies to address socioeconomic stressors in this population.
Abs#0984 #ACR20 @RheumNow
https://t.co/u4YDcfEcSQ
Mrinalini Dey DrMiniDey ( View Tweet)
Time-trend analysis in hospitalised #infection in #lupus
-Incr. rate of hospitalised infections over time
-#Sepsis surpassed #pneumonia as most common hospitalised infection in 2011-12; twice as many sepsis vs pneumonia by 2015-16
Abs#0980 #ACR20 @RheumNow
https://t.co/M8xbMDFUTS https://t.co/ShogvxbhzN
Mrinalini Dey DrMiniDey ( View Tweet)
Withdrawal of MMF may be safely in #SLE patients in remission #ACR20 @RheumNow Dr Chakravarty https://t.co/xnpagKNu96
Sole RetamozoSole ( View Tweet)
Dr Joan Merrill presents a phase 2 trial
use of Iberdomide in patients with #SLE
-Novel MOA —> blocks TF Ailos and Ikaros
Conclusion
-Primary end point was met at week 24
-Effects greater in Aiolos high/Type 2 IFN high
-Iverdomdie was tolerated well
#Lupus
#ACR20
#ACRambassador https://t.co/zpQR9ceV7p
Mohammad A. Ursani MD, RhMSUS DrMAUrsani ( View Tweet)
Dr Richard Furie-> Obinutuzumab for proliferative #lupus nephritis
-Compared to rituximab, has more B-cell depletion in tissue and #SLE patients
-Meaningful benefits over SOC alone on renal response through week 104.
-Phase 3 REGENCY pending.
#ACR20
#ACRambassador
#Rheumatology https://t.co/aPi1yueAiV
Mohammad A. Ursani MD, RhMSUS DrMAUrsani ( View Tweet)
Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not would it affect your Rx of the skin involvement - HCQ, MMF, MTX, Aza & topicals. IL18 sigatures. But I get it. Impt for pathogenesis! @RheumNow #ACR2020 @CRASCRRheum https://t.co/RJh7fEVo4O
Janet Pope Janetbirdope ( View Tweet)
@andreafava representing @jhrheumatology @HopkinsBayview at plenary session! Urine proteomic biomarkers can revolutionize the way we see LN, and decrease need for renal Bx #Acr20 @RheumNow Abst#0936 https://t.co/zGoqmBPddT
Eric Dein ejdein1 ( View Tweet)
Can we use urine testing ( and all the cells, proteins, complements, DNA, rna) to predict LN response? Plenary II @SalemAlmaani @BradRovin @RheumNow #ACR20 @OSUWexMed
alexa meara lexmeara ( View Tweet)
Great talk #ACR20 Integrating bulk and single-cell RNA-sequencing @Kahlenberglab identifies clinically actionable 5-gene signatures that can effectively differentiate DM from cutaneous lupus lesions. @RheumNow @UMIntMed Also out in @JCI_insight https://t.co/uYS6OJH0Hf https://t.co/KR0wwDb5BK
Yu (Ray) Zuo RayZuoMD ( View Tweet)
50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infections or bad lungs as I am not convinced about the risk of PCP/PJP v risk of septra with adverse rxns in SLE. I await an admin database to give me the data @RheumNow #ACR20 https://t.co/3s2S9fIUVe
Janet Pope Janetbirdope ( View Tweet)
Dr. Aggarwal Abs#0955 showed efficacy of IVIG in tx of Dermatomyositis.
How/when do you use IVIG for tx of DM?
@RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)
Efficacy of IVIG in Dermatomyositis Treatment
1st Placebo controlled RCT
1️⃣79% responder by total improvement score vs. 44%
2️⃣Efficacy sustained thru wk 40
3️⃣6% serious AE - thromboembolic event
@RheumNow #ACR20 Abs#0955 #ACRbest https://t.co/715h1UkZ9X
Robert B Chao, MD doctorRBC ( View Tweet)
